ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1091

IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study

Zachary Wallace1, Tina Motazedi1, Michelle Conroy1, Claire Cook1, John Stone2, Hyon Choi3 and Robert Anthony1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The Fc portion of IgG tends to be hypogalactosylated among patients with ANCA-associated vasculitis (AAV) compared with healthy controls1,2,3. Glycan modifications may affect antibody effector functions and therefore serve as a marker of disease activity2. A prior study found that glycosylation patterns differed in PR3- but not MPO-ANCA+ AAV patients with active disease vs remission3. In particular, a higher proportion of total IgG had agalactosylation during active disease vs remission in PR3-ANCA+ AAV. To date, few studies have evaluated glycosylation patterns in MPO-ANCA+ AAV, variations in glycosylation patterns of IgG subclasses in AAV, or these differences in the context of B cell depletion or persistent ANCA positivity.

Methods: We identified patients from the Mass General Brigham (MGB) AAV cohort who had serum samples available from the MGB Biobank or in our prospective MGB AAV cohort. Of these, we included samples from three patients collected at the time of their initial AAV presentation but prior to any treatment and from three patients collected while they were on B cell depletion and their disease was in clinical remission. IgG subclass specific glycosylation was determined by glycopeptide mass spectrometry. We assessed the proportion of IgG1, IgG2, and IgG3, respectively, that was agalactosylated, galactosylated, sialylated, or bisected.

Results: We included six patients, three with newly diagnosed AAV prior to any treatment and three in remission on rituximab for maintenance of remission. All six patients were MPO-ANCA+ by ELISA at the time of sample collection with titers ranging from 5 to 1,075 units (Table 1). Patients with active disease tended to have higher proportions of IgG1, IgG2, and IgG4 that was agalactosylated and lower proportions that were galactosylated when compared with patients in remission (Figures 1a and 1b). Sialylation patterns were similar on IgG1 and IgG2 in active disease vs remission; sialylation was not detected on IgG4 (Figure 1c). Bisecting species were detected on a lower proportion of IgG1 and IgG2 in active disease than in remission (Figure 1d). There was no difference in the proportion of fucosylated IgG1, IgG2, and IgG4 in active disease and remission (Figure 1e).

Conclusion: This proof-of-concept study suggests strong trends in glycosylation pattern differences of IgG1, IgG2, and IgG4 when comparing MPO-ANCA+ AAV patients with active disease vs those in remission, despite having persistently elevated ANCA titers. In particular, active MPO-ANCA+ AAV was characterized by a greater proportion of agalactosylated antibody, similar to what has been described in PR3-ANCA+ AAV. These results, in combination with prior studies, suggest that differences in glycosylation may be a promising avenue for future investigation in both PR3- and MPO-ANCA+ AAV where reliable biomarkers of disease activity are urgently needed. These data call for a full-scale investigation to assess MPO- and PR3-ANCA and leverage longitudinal serial samples to further assess glycosylation patterns as a biomarker.
1Clin Exp Immunol 2002;129:183; 2JASN 2010;21:1103; 3PloS One 2019;14:e0213215

Supporting image 1

Supporting image 2


Disclosures: Z. Wallace, Sanofi, Bristol-Myers Squibb(BMS), Zenas Biopharma, Shionogi, Horizon; T. Motazedi, None; M. Conroy, None; C. Cook, None; J. Stone, Horizon Theraputics, Sanofi, Amgen, Argenx, Bristol-Myers Squibb(BMS), Chemocentryx, Kyverna, Novartis, Palleon Pharmaceuticals, PPD, Q32, Star Therapeutics, Roche, Mirabio, Spruce Biosciences, Steritas, Zenas; H. Choi, Horizon, Allena, LG, Protalix; R. Anthony, None.

To cite this abstract in AMA style:

Wallace Z, Motazedi T, Conroy M, Cook C, Stone J, Choi H, Anthony R. IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/igg-antibody-subclass-glycan-modifications-in-patients-with-anca-associated-vasculitis-in-active-vs-remission-states-a-proof-of-concept-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/igg-antibody-subclass-glycan-modifications-in-patients-with-anca-associated-vasculitis-in-active-vs-remission-states-a-proof-of-concept-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology